Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04781088
Title Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Floor Backes
Indications

endometrial cancer

peritoneum cancer

fallopian tube cancer

ovary epithelial cancer

Therapies

Lenvatinib + Paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Ohio State University Comprehensive Cancer Center Recruiting Columbus Ohio 43210 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field